Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival of less than 10%. Although there are improvements for multimodal therapy of PDAC, surgery still remains the effective way to treat the disease. Combined with adjuvant and/or neoadjuvant treatment, pancreatic surgery is able to enhance the five-year survival up to around 20%. However, pancreatic resection is always associated with a high risk of complications and regarded as one of the most complex fields in abdominal surgery. This review gives a summary on the surgical treatment for PDAC based on the current literature with a special focus on resection techniques.
22 November 2024 in International Journal of Surgery
Introduction: Nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) have been diagnosed increasingly often but still represent rare pancreatic neoplasms. Surgery is a potentially curative approach for patients with NF-PNETs. In recent years, minimally invasive surgery (MIS) has been applied more frequently for surgical resection of NF-PNETs. The evidence for using MIS for NF-PNETs is still being determined and controversial. Materials and Methods: PubMed, Cochrane Library, and the Web of Science database were searched systematically from its inception to July 2023. All studies comparing MIS versus open surgery (OPS) of NF-PNETs were included. The primary outcomes were the incidence of overall postoperative complications and pancreas-specific complications [postoperative pancreatic fistula (POPF) and delayed gastric emptying (DGE)]. The secondary measures were duration of operation, intraoperative blood loss, and length of postoperative hospital stay. Pooled results are presented as odds ratios (OR) or mean difference (MD) with a 95% CI. Results: Five observational studies with a total of 1178 patients were included in the final analysis. The meta-analysis indicated that MIS attained less intraoperative blood loss (MD=−58.59, 95% CI [−92.76 to −24.41], P<0.01) and shorter length of hospital stay (MD=−3.07, 95% CI [−5.28 to −0.87], P<0.01) in contrast to open surgery for NF-PNETs. There were no significant differences concerning operative time (MD=52.04, 95% CI [−8.74 to 112.81], P=0.67), overall postoperative complications (OR=0.78, 95% CI [0.59–1.03], P=0.08), POPF (OR=0.99, 95% CI [0.66–1.47], P=0.94), and DGE (OR=0.58, 95% CI [0.58–1.42], P=0.67). Conclusions: This study demonstrates that minimally invasive surgery for NF-PNETs is safe and associated with a considerably shorter postoperative hospital stay. Further studies are needed to verify the evidence.
Background Brain metastases (BM) from pancreatic cancer have low incidence, carry a poor prognosis, and have limited treatment options. Summarizing disease features and treatment protocols can help understand and improve prognosis. Methods Registered with INPLASY and following PRISMA guidelines, the study searched PubMed, Embase, Scopus, and Web of Science from database inception to 9th January 2025. The Kaplan–Meier method was used to calculate the median survival time and interquartile range (IQR) of Overall Survival (OS), and the corresponding plot was drawn. Results A total of 614 patients with BM from pancreatic cancer were included, originating from 24 case reports & series and 3 retrospective cohort studies. BM was usually multiple (n = 32, 71.1%), and mostly affecting frontal lobes (n = 30, 23.8%). Radiotherapy was primary treatment for BM in both pancreatic surgical (n = 44, 72.1%) and non-surgical (n = 8, 66.7%) groups, and most patients in the non-surgical group underwent chemotherapy and targeted therapy (41.7% vs 6.6%). Patients who underwent pancreatic surgery, had longer time from diagnosis of pancreatic cancer to BM (median: 24.0 vs 11.9 months) but shorter post-BM survival [median: 6.0 (case report/series), 3.0 (retrospective cohort study) vs 10.0 months]. Conclusion This review covers the characteristics, treatment, and prognosis of patients with BM from pancreatic cancer. Radiotherapy may be considered the primary treatment for BM, and pancreatic surgery may impact treatment and prognosis. Large multicenter studies are needed in view of low BM incidence from pancreatic cancer.
29 January 2025 in European Journal of Gastroenterology & Hepatology
Objectives: Opioid administration in acute pancreatitis (AP) exacerbates its severity, prompting concerns regarding the increased requirement for intensive care and its potential impact on patient survival. We aimed to elucidate the influence of analgesic patterns on mortality among patients with AP hospitalized in the ICU. Methods: We included 784 patients (198 receiving opioid monotherapy and 586 receiving opioid polytherapy) from the Medical Information Mart for Intensive Care database. The primary outcome was in-hospital mortality. Propensity score matching was used to account for baseline differences. We used Kaplan–Meier survival curves and multivariate regression models to indicate survival discrepancies and potential associations. Results: Polytherapy group exhibited prolonged hospital survival (79.8 vs. 57.3 days, P < 0.001); polytherapy was associated with decreasing in-hospital mortality adjusted for confounders (HR = 0.49, 95% CI: 0.26–0.92; P = 0.027). Stratification analysis indicated that patients receiving adjunctive acetaminophen had prolonged hospital survival (opioid vs. opioid + acetaminophen, P < 0.001; opioid vs. opioid + NSAIDs + acetaminophen, P = 0.026). Opioid polytherapy benefited patients with APACHE III scores >83 and those with mean oral morphine equivalent >60 mg/day (HR = 0.17, 95% CI: 0.1–0.3, P < 0.001 and HR = 0.32, 95% CI: 0.2–0.52, P < 0.001, respectively). Conclusion: Our findings suggest that an opioid-based analgesic regimen offers a survival advantage for patients with AP, particularly those in critical condition or with concerns about opioid use. This approach provides a viable clinical strategy for pain management. Further randomized clinical trials are warranted to validate these results.
Background: At the time of diagnosis, 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are already at an unresectable advanced stage. The median overall survival (mOS) with traditional AG chemotherapy is only 8.5 months. The bispecific antibody Cadonilimab targeting PD-1 and CTLA-4 has shown immuno-oncological synergy in solid tumors, but evidence in PDAC is limited.Methods: This study is a single-center retrospective study that included 14 patients with advanced pancreatic ductal adenocarcinoma. These patients received Cadonilimab (10 mg/kg, Q3W) in combination with AG chemotherapy. The primary endpoint was the disease control rate (DCR, RECIST 1.1).Results: The disease control rate (DCR) reached 85.7%, and the objective response rate (ORR) was 14.3%; the median progression-free survival (mPFS) was 7.87 months, and the median overall survival (mOS) was 11.45 months. Among patients with a decrease in CA19-9, the median overall survival was significantly prolonged (12.92 vs 8.89 months, P = 0.027); patients with a platelet-lymphocyte ratio (PLR) ≤ 165.62 had a significantly better mOS (12.37 vs 8.74 months, P = 0.025). Although the incidence of grade 3 treatment-related adverse events was 57.1%, no grade 4 treatment-related toxic events were observed.Conclusion: In conclusion, cadonilimab combined with AG chemotherapy demonstrated promising antitumor activity and manageable safety in PDAC. Dynamic monitoring of PLR and CA19–9 may aid efficacy evaluation, but these exploratory findings require confirmation in prospective multicenter trials.
28 May 2025 in European Journal of Gastroenterology & Hepatology